Skip to content

Opening act — London Life Sciences Week

Onyx Global
Life Sciences Forum

Where capital meets science & policy meets pace

  • 15–16 November 2026
  • The Shard, London
  • ~1,000 attendees

Executives, investors, policymakers, scientists & students — one room, two days.

Get Tickets

Core Themes

Three forces shaping life sciences

Capital Allocation

Where is smart money moving in biotech? We examine how capital is being deployed across therapeutic areas, geographies, and modalities — and whether the math adds up.

Pharma-Biotech Partnerships

The partnership landscape is shifting from licensing deals to full acquisitions. We explore the new logic of pharma-biotech collaboration, and what founders and investors need to know.

Regulation & Speed to Clinic

How regulatory bodies across the US, EU, and UK are accelerating — or blocking — the path from discovery to patient. We map the timelines, track the bottlenecks, and ask what must change.

About Onyx

Building the signal layer for life sciences

Onyx is a research intelligence company focused on biotech, pharma, and the life sciences investment ecosystem. We produce original analysis, host high-conviction events, and operate tools that help decision-makers move faster with better information.

50+ Fortune 500 readers
2 Sold-out events at The Shard
30+ CEO interviews published
1st Forum of its kind in London

Limited to ~1,000 attendees. Reserve your place early.

Get Tickets

Attendees from

Amgen
Gilead Sciences
Regeneron
Moderna
Biogen
Vertex Pharmaceuticals
Bristol Myers Squibb
AstraZeneca
Novo Nordisk
Illumina

A different kind of life sciences event.

Get Tickets

Programme

Two days. Two frontiers. No filler.

Day 1 — Sunday 15 November

Cell & Gene Therapies

09:00

I. The State of Biotech Capital

Where funding is flowing, where it's drying up, and what the LP-GP-founder dynamic looks like heading into 2027.

10:15

II. Manufacturing & Supply Chain

Autologous vs. allogeneic scale-up, viral vector bottlenecks, and the economics of getting CGTs to patients at commercial scale.

11:30

III. Regulatory Pathways for Advanced Therapies

ATMP frameworks, accelerated approvals, and what the FDA-EMA-MHRA divergence means for gene therapy sponsors.

Day 2 — Monday 16 November

Small Molecules & Biologics

09:00

IV. Drug Pricing & Market Access

IRA fallout, NICE reform, and the global pricing chessboard. What investors and pharma execs are actually modelling.

10:15

V. The Partnership Equation

M&A vs. licensing vs. co-development. How the pharma-biotech deal landscape is being redrawn.

11:30

VI. AI, Data & the New R&D Stack

From target identification to clinical trial optimisation. Separating the signal from the hype in computational biology.

Be part of the programme. Applications now open.

The Protocol

How this day works

01

Arrive with context

Every registered attendee receives a pre-forum briefing pack — original Onyx research, data snapshots, and speaker briefs. You arrive knowing the terrain.

02

Hear from leaders

Six curated sessions with founders, investors, regulators, and scientists. No sponsor slots. No filler. Every minute earns its place on the stage.

03

Enter the week better prepared

The Forum is designed as the opening act. You leave with sharper conviction, new relationships, and a framework for the week of meetings ahead.

Access

Choose your path in

All passes include full-day access, the pre-forum briefing pack, and post-event materials.

Executive Pass
  • Priority seating & front-row access
  • Exclusive networking reception
  • 1-to-1 meeting scheduling
  • Private briefing with Onyx analysts
  • Full post-event research report
Industry Pass Most popular
  • Full-day general admission
  • Networking breaks & lunch
  • Access to all six sessions
  • Pre-forum briefing pack
  • Digital post-event materials
Student & Early Career
  • Full-day general admission
  • Dedicated student networking hour
  • Mentorship matching (limited)
  • Pre-forum briefing pack
  • Career resources from Onyx